Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Grade I Neuroendocrine Carcinoma”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)Study completedNCT01563354
What this trial is testing

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

Who this might be right for
Neuroendocrine Carcinoma of the Lung and Thymus
Novartis Pharmaceuticals 124
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Looking for participantsNCT06472388
What this trial is testing

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsProgressionNeuroendocrine Tumor Grade 1+4 more
AC Camargo Cancer Center 100
Early research (Phase 1)Study completedNCT00073944
What this trial is testing

BCX-1777 in Treating Patients With Refractory Cancer

Who this might be right for
Cancer
BioCryst Pharmaceuticals
Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Testing effectiveness (Phase 2)Looking for participantsNCT07115043
What this trial is testing

Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+6 more
AstraZeneca 60
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Early research (Phase 1)Active Not RecruitingNCT04616248
What this trial is testing

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8+10 more
University of Southern California 14
Early research (Phase 1)Study completedNCT01204476
What this trial is testing

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Who this might be right for
Gastrin-Producing Neuroendocrine TumorLung Carcinoid TumorMetastatic Digestive System Neuroendocrine Tumor G1+12 more
National Cancer Institute (NCI) 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT04471727
What this trial is testing

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Who this might be right for
Small-Cell Lung CancerNeuroendocrine Carcinoma
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232
Early research (Phase 1)Ended earlyNCT01769222
What this trial is testing

Ipilimumab and Local Radiation for Selected Solid Tumors

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+31 more
Stanford University 3
Not applicableLooking for participantsNCT04464122
What this trial is testing

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmNeuroendocrine Tumor Grade 1+2 more
University of Roma La Sapienza 60
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT00019019
What this trial is testing

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerKidney Cancer+6 more
National Institutes of Health Clinical Center (CC) 70
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+17 more
Fundación de investigación HM 25
Testing effectiveness (Phase 2)UnknownNCT00637637
What this trial is testing

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Who this might be right for
Cancer
Oncology Institute of Southern Switzerland 60
Testing effectiveness (Phase 2)Study completedNCT00445965
What this trial is testing

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+7 more
Memorial Sloan Kettering Cancer Center 78
Load More Results
40